Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Simufilam (Primary)
Indications Alzheimer's disease
Focus Biomarker; Therapeutic Use
Sponsors Cassava Sciences

Most Recent Events

30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
26 Jul 2021 According to a Cassava Sciences media release, results from this study were presented at the Alzheimers Association International Conference (AAIC)
26 Jul 2021 Results published in the Cassava Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com